Given the release of multiple damage-associated molecular patterns (DAMPs) and alarmins (ATP, HMGB1, etc) by tumor cells treated with LTX-315 in vitro (8, 10, 11) and the known capacities of DAMPs/alarmins to induce DC maturation (19, 20), it has been proposed that the DAMPs/alarmins released by LTX-315-treated tumor cells are responsible for triggering the maturation of TiDCs and subsequent tumor-specific immune response (6). Here, HMGB1 is linked to neoplasm.